



January 6, 2015

## **Fate Therapeutics to Present at Biotech Showcase 2015**

SAN DIEGO, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the Company's programs at the 7<sup>th</sup> Annual Biotech Showcase conference on Monday, January 12, 2015 at 11:30 am PST in San Francisco, CA.

A live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at [www.fatetherapeutics.com](http://www.fatetherapeutics.com). An archived replay of the webcast will be available on the Company's website for 30 days after the conference.

### **About Fate Therapeutics, Inc.**

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases. The Company's approach utilizes established pharmacologic modalities, such as small molecules, to program the fate and function of cells *ex vivo*. The Company's lead product candidate, PROHEMA<sup>®</sup>, is an *ex vivo* programmed hematopoietic cellular therapeutic, which is currently in clinical development for the treatment of hematologic malignancies and rare genetic disorders in patients undergoing hematopoietic stem cell transplantation (HSCT). The Company is also using its proprietary induced pluripotent stem cell platform to develop *ex vivo* reprogrammed hematopoietic and myogenic cellular therapeutics. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).

CONTACT: Renee Leck, Stern Investor Relations, Inc.

212.362.1200, [renee@sternir.com](mailto:renee@sternir.com)